Company intelligence / Profile preview

Parallel Ventures

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Parallel Bio has demonstrated the viability of its immune organoid platform with 8 pharmaceutical partners testing more than 50 drugs and immunotherapies. A notable early success is validation of Centivax's universal flu vaccine candidate (Centi-Flu) in human immune organoids, demonstrating broad immune responses against multiple influenza strains.

Therapeutic areas: ImmunologyOther
Modalities: Organoid-based platformvaccinesmonoclonal antibodiescheckpoint inhibitorsimmunotherapies
Industry: Non-Drug Biotech

Partnerships

8 pharmaceutical partners including three Fortune 500 companiesCentivax

Beyond the preview

Go deeper on Parallel Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parallel Ventures.

Explore the full profile